indication

For potential use in the treatment of Alzheimer's disease.

pharmacology

The drug may compensate for neurotransmitter deficits and can in different circumstances, compensate for hyperactivity in the same neurotransmitter pathways. The drug can counteract and prevent disturbances between monoaminergic and other transmitter systems in the CNS.

mechanism of action

Dihydroergotoxine is a mixture of three different ergotaman-3',6',18-triones, dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent and a nootropic agent. The mechanism of its therapeutic actions is not clear, but it can act as an alpha-adrenergic antagonist and a dopamine agonist. Specifically it binds to the Dopamine D2 receptor and the GABAA receptor.

drug interactions

Acebutolol: Ischemia with risk of gangrene

Almotriptan: Possible severe and prolonged vasoconstriction

Atenolol: Ischemia with risk of gangrene

Bisoprolol: Ischemia with risk of gangrene

Carvedilol: Ischemia with risk of gangrene

Delavirdine: The antiretroviral agent may increase the ergot derivative toxicity

Efavirenz: The antiretroviral agent may increase the ergot derivative toxicity

Eletriptan: Possible severe and prolonged vasoconstriction

Erythromycin: Possible ergotism and severe ischemia with this combination

Esmolol: Ischemia with risk of gangrene

Frovatriptan: Possible severe and prolonged vasoconstriction

Isosorbide Dinitrate: Possible antagonism of action

Isosorbide Mononitrate: Possible antagonism of action

Labetalol: Ischemia with risk of gangrene

Metoprolol: Ischemia with risk of gangrene

Nadolol: Ischemia with risk of gangrene

Naratriptan: Possible severe and prolonged vasocontriction

Nitroglycerin: Possible antagonism of action

Oxprenolol: Ischemia with risk of gangrene

Pindolol: Ischemia with risk of gangrene

Propranolol: Ischemia with risk of gangrene

Timolol: Ischemia with risk of gangrene